Shanghai Longwood Biopharmaceuticals Co., Ltd.

7 clinical trials · Sponsor

Record	Firm	Date
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo (NCT07556471)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2026-05-31
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis (NCT07370909)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2026-01-30
A Multiple Ascending Dose Study of LW402 in Healthy Volunteers (NCT07546149)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2025-10-15
Study of LW231 in Participants With Chronic Hepatitis B (NCT07179575)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2025-10-01
Study of LW402 in Moderate-to-Severe Atopic Dermatitis (NCT07186387)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2023-05-11
Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis (NCT06800157)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2023-02-27
A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection (NCT06311734)	Shanghai Longwood Biopharmaceuticals Co., Ltd.	2022-06-21

Every clearance here is in the API, with alerts when new ones post.